Bullseye Chart: The Psychedelic Drug Development Pipeline Post published:February 8, 2023 Post category:2022 Year in Review
Panel: Neuroimaging in Psychedelic Research Post published:February 7, 2023 Post category:2022 Year in Review
A Perspective from the ‘Reimagining Psychedelic Trials’ Working Group Post published:February 2, 2023 Post category:2022 Year in Review
Historical Insights on the Psychedelic Renaissance Post published:February 2, 2023 Post category:2022 Year in Review
A Spotlight on Psychedelic Research Methods Post published:February 2, 2023 Post category:2022 Year in Review
Panel: Psychedelic Research Methods Post published:February 2, 2023 Post category:2022 Year in Review
The Agenda for Economic Analyses of Psychedelic-assisted Therapy Post published:February 1, 2023 Post category:2022 Year in Review
A Perspective on Providers: Scaling PAT in a Time of Therapist Shortages Post published:February 1, 2023 Post category:2022 Year in Review
Making “Access” A Meaningful Part of Every Conversation about Psychedelic Therapy Post published:February 1, 2023 Post category:2022 Year in Review
Psychedelic Therapies: From Approvals to Access Post published:February 1, 2023 Post category:2022 Year in Review